FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesImport/Export of Clinical Supplies – An Overview
Topics: Logistics, Supply Chain
Webinar
Free
2018 GCSG US Conference Recap Video
Topic: Conference
Video
Members
COVID-19’s Impact on the Supply Chain in Asia-Pacific
Topics: COVID-19, Supply Chain
Webinar
Free
